echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > 2022 ESMO Extranodal NK/T-cell Lymphoma Treatment New Hope? The safety and efficacy of PLM60+ Pecopetase treatment are encouraging!

    2022 ESMO Extranodal NK/T-cell Lymphoma Treatment New Hope? The safety and efficacy of PLM60+ Pecopetase treatment are encouraging!

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Extranodal NK/T cell lymphoma (ENKTCL) is a rare invasive, non-Hodgkin lymphoma that originates from NK cells and T lymphocytes and is highly aggressive, rapid progression, and poor



    Research Methods

    Patients included in the study were adult patients



    Figure 1 Study design


    Results of the study
    • Patient baseline features

    As of 15 February 2022, a total of 31 patients were enrolled (Phase I: 21, Phase II: 10).



    Table 1 Patient baseline features


    • security

    All 31 patients experienced "treatment-phase" adverse events (TEAE), and 87.



    Figure 2 TEAE occurred in 31 patients


    • PK result

    The PK profile of PLM60 did not change



    Table 2 PK results (left: total mitoxantrone; Right: Free mitoxantraquinone ( )


    • efficacy

    Efficacy was assessed in all 31 patients, with a complete response (CR) rate of 61.



    Table 3 Efficacy results

    Figure 3 Results of efficacy in patients treated at the beginning

    Conclusion of the study

    PLM60 has good PK characteristics, and the PK characteristics are not affected
    after combination with pementlease.

    The PLM60+ pementlease protocol has shown significant efficacy and manageable safety
    in patients with initial treatment of ENKTCL.

    Source: Y.
    Huang, et al.
    2022ESMO.
    Abstract #625MO.
    Edit: Wenting Review: Mia Typesetting: Wenting Execution: moly

    Poke "Read the original article" to see more

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.